617P Durvalumab after chemoradiotherapy in non-small cell lung cancer with EGFR mutation: A real-world study (HOT2101)
H. Kikuchi(Obihiro Kosei General Hospital), S. Oizumi, Kunihiro Tsuji(Ishikawa Prefectural Central Hospital), K. Yokoo(Teine Keijinkai Hospital), H. Mizugaki, Toshiyuki Sumi(Hakodate National Hospital), Hiroyuki Minemura(Fukushima Medical University), Taichi Takashina(Hokkaido University), Ryo Morita, Hirotaka Tanaka(Jikei University School of Medicine), Kyoji Tsurumi(Sendai Kousei Hospital), Kae Nakamura(Nagoya University), Yoshiaki Kitamura(Kushiro City General Hospital), Noriyuki Kimura(Oita University), H. Yokouchi(Japan Cancer Society), Satoshi Konno(Hokkaido University), Kengo Ito(National Center for Geriatrics and Gerontology), Jun Sugisaka(Sendai Kousei Hospital), Kyoichi Kobashi(Muroran Institute of Technology), Yosuke Kawai(Tohoku University)
Cited by 1
Related Papers
High performance plasma amyloid-β biomarkers for Alzheimer’s disease
|Nature|2018|1.7k
Discrimination between Alzheimer Dementia and Controls by Automated Analysis of Multicenter FDG PET
|NeuroImage|2002|839
A Randomized Controlled Trial of Multicomponent Exercise in Older Adults with Mild Cognitive Impairment
|PLoS ONE|2013|388
Profiling Preexisting Antibodies in Patients Treated With Anti–PD-1 Therapy for Advanced Non–Small Cell Lung Cancer
|JAMA Oncology|2018|370
Somatosensory Homunculus as Drawn by MEG
|NeuroImage|1998|342